Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance

Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an announcement.

Recce Pharmaceuticals reported a widened half-year loss of $16.6 million to 31 December 2025, more than doubling the prior period as it increased research and development spending, with net tangible assets per share falling further into negative territory and no dividends declared. The period also marked the passing of founder and technology inventor Dr Graham Melrose, underscoring a significant leadership and legacy transition for the company.

Operationally, the company advanced its anti-infective portfolio, including statistically significant preclinical efficacy data for topical R327G in resistant burn wound infections and strong nebulised RECCE 327 results in a pneumonia model caused by carbapenem-resistant Acinetobacter baumannii. Recce also progressed patient dosing in a registrational Phase 3 trial for diabetic foot infections in Indonesia, secured a Hong Kong patent to 2041, and obtained an Advanced Overseas Finding covering up to A$85 million of qualifying R&D, alongside expected R&D tax rebate inflows to help fund ongoing operations.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

More about Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd is an Australian biotechnology company focused on developing synthetic anti-infective therapies to address serious and antibiotic-resistant infections. Its lead candidate, RECCE 327, targets high-priority pathogens in indications such as diabetic foot infections, hospital- and ventilator-acquired pneumonia, and bioterrorism-related infectious threats.

Average Trading Volume: 135,998

Technical Sentiment Signal: Buy

Current Market Cap: A$164.8M

See more data about RCE stock on TipRanks’ Stock Analysis page.